A Brief Overview of Ribonucleic Acid Interference (RNAi) for | 93436

Journal of Research in Medical and Dental Science
eISSN No. 2347-2367 pISSN No. 2347-2545

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

A Brief Overview of Ribonucleic Acid Interference (RNAi) for Combating Immune Disorders

Author(s): Manisha Jayanand*, Sanjiv Mittal, Sushma Chaturvedi, Durgesh Wadhwa


In almost all human cells, the RNA interference (RNAi) system controls mRNA stability as well as translation. While tiny ds RNA particles are effective in inducing RNAi silence of particular genes, their clinical application has been fraught with d?f??cu?t?es about safety and ef??c?c?? However, in August 2018, the ??e?d entered a new phase with the approval of patisiran, the very initial RNAi-based medicine, by the US Food & Drug Administration. Rapid advancements in our knowledge of RNAi-based processes have led to the use of this potent technique in gene function research as well as therapeutic applications for disease treatment. Two-dimensional pharmaceutical designs for RNAi-based treatments rely solely on the ???d??g of excellent Watson-Crick base pairing between the RNAi guide strand and the target, allowing for fast construction and testing of RNAi triggers. Despite the great s?ec???c?t? of activity, siRNA may produce a series of untargeted consequences, because of the toxicity they cause, prohibit their usage at large dose. We address important breakthroughs in the development and design of RNAi medicines that led to this historic accomplishment, the present status of clinical pipeline, and possibilities for future advancements, including new RNAi pathway therapeutics that use mechanisms other than post-translational RNAi silencing

Share this article